Quality process measures for rheumatoid arthritis: Performance from members enrolled in a national health plan

Journal of Managed Care Pharmacy

Volumn 21, Issue 2, 2015, Pages 135-143

  Tkacz, Joseph ^a   Ellis, Lorie A ^b   Meyer, Roxanne ^b   Bolge, Susan C ^b   Brady, Brenna L ^a   Ruetsch, Charles ^a  

^a Health Analytics   (United States)

^b Health Economics and Outcomes Research Janssen Scientific Affairs   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CREATININE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; METHOTREXATE; AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; LEFLUNOMIDE; PENICILLAMINE;

ADULT; AGE; ARTICLE; BLOOD CELL COUNT; CHARLSON COMORBIDITY INDEX; CHRONIC LUNG DISEASE; CHRONIC PAIN; CREATININE BLOOD LEVEL; DATA BASE; DEPRESSION; DIABETES MELLITUS; DISORDERS OF LIPID METABOLISM; DRUG USE; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GENDER; HUMAN; HYPERTENSION; HYPOTHYROIDISM; ICD-9; LIVER DISEASE; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; OSTEOARTHRITIS; OSTEOPOROSIS; PATIENT CARE; PRESCRIPTION; RHEUMATOID ARTHRITIS; TOTAL QUALITY MANAGEMENT; ACCOUNTABLE CARE ORGANIZATION; COMORBIDITY; DECISION SUPPORT SYSTEM; DEMOGRAPHY; HEALTH CARE COST; HEALTH CARE QUALITY; HEALTH CARE UTILIZATION; MENTAL CAPACITY; OUTCOME ASSESSMENT; PUBLIC HEALTH; UNITED STATES; AGED; ARTHRITIS, RHEUMATOID; MIDDLE AGED;

ADULT; AGED; ARTHRITIS, RHEUMATOID; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; PROCESS ASSESSMENT (HEALTH CARE); QUALITY OF HEALTH CARE;

EID: 84930176262     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2015.21.2.135     Document Type: Article

References (44)

1. Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum.2010;62(9):2569-81.
2. Centers for Disease Control and Prevention. Prevalence of doctor-diagnosed arthritis and arthritis-attributable activity limitation-United States, 2007-2009. MMWR Morb Mortal Wkly Rep. 2010;59(39):1261-65.
3. Helmick CG, Felson DT, Lawrence RC, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum. 2008;58(1):15-25.
4. Centers for Disease Control and Prevention. National and state medical expenditures and lost earnings attributable to arthritis and other rheumatic conditions-United States, 2003. MMWR Morb Mortal Wkly Rep.2007;56(1):4-7.
5. Kale MS, Bishop TF, Federman AD, Keyhani S. Trends in the overuse of ambulatory health care services in the United States. JAMA Intern Med.2013;173(2):142-48.
6. National Research Council. (1990). Medicare: A Strategy for Quality Assurance, Volume 1. Washington, D.C.: The National Academies Press.
7. Scott DL. Biologics-based therapy for the treatment of rheumatoid arthritis. Clin Pharmacol Ther. 2012;91(1):30-43.
8. Bonafede MM, Fox KM, Johnson BH, Watson C, Gandra SR. Factors associated with the initiation of disease-modifying antirheumatic drugs in newly diagnosed rheumatoid arthritis: a retrospective claims database study. Clin Ther. 2012;34(2):457-67.
9. Lacaille D, Anis AH, Guh DP, Esdaile JM. Gaps in care for rheumatoid arthritis: a population study. Arthritis Rheum. 2005;53(2):241-48.
10. Westhoff G, Schneider M, Raspe H, et al. Advance and unmet need of health care for patients with rheumatoid arthritis in the German population-results from the German Rheumatoid Arthritis Population Survey (GRAPS). Rheumatology (Oxford). 2009;48(6):650-57.
11. Schmajuk G, Schneeweiss S, Katz JN, et al. Treatment of older adult patients diagnosed with rheumatoid arthritis: improved but not optimal. Arthritis Rheum. 2007;57(6):928-34.
12. Shipton D, Glazier RH, Guan J, Badley EM. Effects of use of specialty services on disease-modifying antirheumatic drug use in the treatment of rheumatoid arthritis in an insured elderly population. Med Care.2004;42(9):907-13.
13. Chassin MR, Loeb JM. The ongoing quality improvement journey: next stop, high reliability. Health Aff (Millwood). 2011;30(4):559-68.
14. Adhikesavan LG, Newman ED, Diehl MP, Wood GC, Bili A. American College of Rheumatology quality indicators for rheumatoid arthritis: benchmarking, variability, and opportunities to improve quality of care using the electronic health record. Arthritis Rheum. 2008;59(12):1705-12.
15. National Committee for Quality Assurance, Physician Consortium for Performance Improvement, American College of Rheumatology. Rheumatoid arthritis: physician performance measurement set. July 2008. Available at:http://rheumatoidarthritis.semarthritisrheumatism.com/Content/PDFs/RR-NCQA-Arthritis.pdf. Accessed December 14, 2014.
16. National Quality Forum. Measures, reports & tools. Available at: http://www.qualityforum.org/Measures_Reports_Tools.aspx. Accessed January 2, 2015.
17. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-83.
18. Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012;64(5):625-39.
19. Zachariae H. Methotrexate side-effects. Br J Dermatol. 1990;122(Suppl 36):127-33.
20. Jones KW, Patel SR. A family physician's guide to monitoring methotrexate. Am Fam Physician. 2000;62(7):1607-12, 1614.
21. Whiting-O'Keefe QE, Fye KH, Sack KD. Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am J Med. 1991;90(6):711-16.
22. Widemann BC, Adamson PC. Understanding and managing methotrexate nephrotoxicity. Oncologist. 2006;11(6):694-703.
23. Watson J, Round A, Hamilton W. Raised inflammatory markers. BMJ. 2012;344:e454.
24. Costenbader KH, Chibnik LB, Schur PH. Discordance between erythrocyte sedimentation rate and C-reactive protein measurements: clinical significance. Clin Exp Rheumatol. 2007;25(5):746-49.
25. Osei-Bimpong A, Meek JH, Lewis SM. ESR or CRP? A comparison of their clinical utility. Hematology. 2007;12(4):353-57.
26. Wolfe F. Comparative usefulness of C-reactive protein and erythrocyte sedimentation rate in patients with rheumatoid arthritis. J Rheumatol.1997;24(8):1477-85.
27. Blackburn WD Jr. Validity of acute phase proteins as markers of disease activity. J Rheumatol Suppl. 1994;42:9-13.
28. Crowson CS, Rahman MU, Matteson EL. Which measure of inflammation to use? A comparison of erythrocyte sedimentation rate and C-reactive protein measurements from randomized clinical trials of golimumab in rheumatoid arthritis. J Rheumatol. 2009;36(8):1606-10.
29. Devlin J, Gough A, Huissoon A, et al. The acute phase and function in early rheumatoid arthritis. C-reactive protein levels correlate with functional outcome. J Rheumatol. 1997;24(1):9-13.
30. Grindulis KA, Calverley M, Constable TJ, Forster PJ, Ahmed ME, McConkey B. A comparison between clinical and laboratory tests in rheumatoid arthritis. Scand J Rheumatol. 1983;12(3):285-88.
31. Jansen LM, van der Horst-Bruinsma IE, van Schaardenburg D, Bezemer PD, Dijkmans BA. Predictors of radiographic joint damage in patients with early rheumatoid arthritis. Ann Rheum Dis. 2001;60(10):924-27.
32. Jansen LM, van Schaardenburg D, van Der Horst-Bruinsma IE, Bezemer PD, Dijkmans BA. Predictors of functional status in patients with early rheumatoid arthritis. Ann Rheum Dis. 2000;59(3):223-26.
33. Kay J, Morgacheva O, Messing SP, et al. Clinical disease activity and acute phase reactant levels are discordant among patients with active rheumatoid arthritis: acute phase reactant levels contribute separately to predicting outcome at one year. Arthritis Res Ther. 2014;16(1):R40.
34. Keenan RT, Swearingen CJ, Yazici Y. Erythrocyte sedimentation rate and C-reactive protein levels are poorly correlated with clinical measures of disease activity in rheumatoid arthritis, systemic lupus erythematosus and osteoarthritis patients. Clin Exp Rheumatol. 2008;26(5):814-19.
35. Mallya RK, de Beer FC, Berry H, Hamilton ED, Mace BE, Pepys MB. Correlation of clinical parameters of disease activity in rheumatoid arthritis with serum concentration of C-reactive protein and erythrocyte sedimentation rate. J Rheumatol. 1982;9(2):224-28.
36. Ward MM. Relative sensitivity to change of the erythrocyte sedimentation rate and serum C-reactive protein concentration in rheumatoid arthritis. J Rheumatol. 2004;31(5):884-95.
37. Kobelt G, Eberhardt K, Jonsson L, Jonsson B. Economic consequences of the progression of rheumatoid arthritis in Sweden. Arthritis Rheum.1999;42(2):347-56.
38. Rat AC, Boissier MC. Rheumatoid arthritis: direct and indirect costs. Joint Bone Spine. 2004;71(6):518-24.
39. Hussey PS, Wertheimer S, Mehrotra A. The association between health care quality and cost: a systematic review. Ann Intern Med. 2013;158(1):27-34.
40. Weeks WB, Gottlieb DJ, Nyweide DE, et al. Higher health care quality and bigger savings found at large multispecialty medical groups. Health Aff (Millwood). 2010;29(5):991-97.
41. Curtis JR, Chastek B, Becker L, et al. Further evaluation of a claimsbased algorithm to determine the effectiveness of biologics for rheumatoid arthritis using commercial claims data. Arthritis Res Ther. 2013;15(2):404.
42. Jean S, Candas B, Belzile É, et al. Algorithms can be used to identify fragility fracture cases in physician-claims databases. Osteoporos Int.2012;23(2):483-501.
43. Tyree PT, Lind BK, Lafferty WE. Challenges of using medical insurance claims data for utilization analysis. Am J Med Qual. 2006;21(4):269-75.
44. Anderson J, Caplan L, Yazdany J, et al. Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care Res (Hoboken). 2012;64(5):640-47.